Gavrić Morena, Gabrić Nikica, Jagić Jurica, Cović Ana
University Eye Hospital "Svjetlost", Zagreb, Croatia.
Coll Antropol. 2011 Sep;35 Suppl 2:39-41.
In this prospective study we wanted to report our experience and to evaluate the efficacy and safety of Ex-press Mini-Glaucoma Shunt implantation under a superficial scleral flap, as a newly and improved surgical technology in a treatment of POAG (Primary open-angle glaucoma) and refractory glaucoma. 44 eyes (35 patients) underwent an implantation of Ex-Press Mini Glaucoma Shunt. We had 21 patients with POAG (60%) and 14 patients with PEXG-pseudoexfoliation glaucoma (40%). The follow-up period was 8.62 + 7.48 months (range 2-22 months). Main outcome measures included postoperative IOP control, postoperative medications and early postoperative complications. The IOP was measured in the following postoperative time-points of 1 day, 1 week, 1, 3, 6, 9 and 12 months. The mean IOP values 1 year postoperatively were reduced for 52.8% compared to preoperative values and the use of medications were reduced for 77%. We had complications like postoperative hypotony (3.5%), choroidal ablation (7%), intraocular hemorrhage (3.5%) and postoperative shunt closure (3.5%). The Ex PRESS Mini Glaucoma Shunt implanted under a superficial scleral flap is relatively safe and effective surgical procedure and provides satisfactory IOP control and medication reduction. However, device related complications remain still a problem.
在这项前瞻性研究中，我们希望报告我们的经验，并评估在浅层巩膜瓣下植入Ex-press微型青光眼分流器作为一种新的改良手术技术治疗原发性开角型青光眼（POAG）和难治性青光眼的疗效和安全性。44只眼（35例患者）接受了Ex-Press微型青光眼分流器植入术。我们有21例原发性开角型青光眼患者（60%）和14例假性剥脱性青光眼（PEXG）患者（40%）。随访期为8.62±7.48个月（范围2 - 22个月）。主要观察指标包括术后眼压控制、术后用药情况和术后早期并发症。在术后1天、1周、1、3、6、9和12个月的以下时间点测量眼压。术后1年的平均眼压值较术前降低了52.8%，用药量减少了77%。我们出现了如术后低眼压（3.5%）、脉络膜脱离（7%）、眼内出血（3.5%）和术后分流器堵塞（3.5%）等并发症。在浅层巩膜瓣下植入Ex PRESS微型青光眼分流器是一种相对安全有效的手术方法，能提供令人满意的眼压控制和用药量减少效果。然而，与装置相关的并发症仍然是一个问题。
